PharmacokineticParameter UlipristalAcetate PGL4002 Plasma Total Radioactivity Whole Blood Total Radioactivity Cmax (ng/mL or ngeq/mL) 141 ± 31.0 39 ± 8.1 281 ± 41.7 157 ± 34.3 tmax (h) 0.7 ± 0.48 1.0 ± 0.33 0.9 ± 0.38 1.0 ± 0.33 t1/2 (h) 52 ± 9.1 37 ± 15.1 133 ± 65.4 279 ± 120 AUC0-t(h·ng/mL or ng eq/mL) 423 ± 107 136 ± 44 4733 ±1508 2299 ± 796 AUC0-∞ (h·ng/mL or ngeq/mL) 438 ± 117 143 ± 48 7265 ± 2618 9074 ± 3205 Cmax: peak concentration; tmax: time to Cmax; t1/2: terminal half-life; AUC0-t: area under the plasma concentration–time curve to the last quantifiable sample; AUC0-∞: area under the plasma concentration–time curve extrapolated to infinity.

Table 1: Pharmacokinetic parameters of ulipristal acetate, PGL4002 and total radioactivity in healthy premenopausal women (n=5) after a single 20-mg dose. Data are presented as mean ± standard deviation

Goto home»